Papers And Originals

Clinical Evaluation of Perhexiline Maleate in Patients with Angina Pectoris

Br Med J 1971; 4 doi: (Published 04 December 1971) Cite this as: Br Med J 1971;4:586

This article has a correction. Please see:

  1. C. J. Burns-Cox,
  2. K. P. Chandrasekhar,
  3. H. Ikram,
  4. T. H. Peirce,
  5. J. Pilcher,
  6. C. D. M. Quinlan,
  7. J. Russell Rees


    This paper reports a double-blind trial of a new antianginal drug, perhexiline. Fifty-five patients suffering from angina pectoris were studied for periods of 12 or 24 weeks in a cross-over comparison against a placebo in four centres in the United Kingdom and Ireland. Perhexiline was effective in most patients as judged by reducing the number of anginal attacks in 84% and the consumption of glyceryl trinitrate tablets in 64%. The major side effect, dizziness, noted in one-third of the patients, may be dose/body-weight related. Perhexiline is a valuable new agent for the treatment of patients with angina, especially those who do not respond to other antianginal agents.